NCT05053880 2021-11-19A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma MultiformeAccendatech USA Inc.Phase 1/2 Unknown48 enrolled